James Nelson CV 33016

JAMES EDWARD NELSONCURRICULUM VITAE

Home Address:2036 218th PL NESammamish, WA 98074Phone: (206) 794-2998

EDUCATIONDegrees

1988 BS Biology, Alma College, Alma, Michigan

1994 PhD Department of Molecular Biology and Genetics, Wayne State University School of Medicine, Detroit, Michigan. Minor: Department of Immunology and Microbiology

Dissertation: Detailed Characterization of the Human Protamine Gene Cluster Region; Physical Analysis, Isolation of the Transition Protein 2 Gene and Complete DNA Sequence Analysis.

Advisor: Stephen A. Krawetz, Ph.D., Charlotte B. Failing Professor of Fetal Therapy and Diagnosis. Department of Molecular Biology and Genetics, Obstetrics and Gynecology and Center for Molecular Medicine and Genetics

9/03-6/04 Clinical Trials Certificate Program, University of Washington Extension-Seattle

9/15-present Data Science Master’s Program (online), Indiana University-BloomingtonGraduate Certificate (awarded upon completion of 12 credit hours) May 2016

EMPLOYMENT AND TRAINING4/94-10/94 Research Faculty, Dept. of Molecular Biology and Genetics, Wayne State

University, Detroit, MI

11/94-8/98 Senior Fellow, Division of Medical Genetics, Markey Molecular Medicine Center, University of Washington School of Medicine. Seattle, WA. Laboratory Director: Mark Kay M.D., Ph.D.

8/98-8/99 Postdoctoral Fellow, Division of Pediatric Genetics, Stanford University School of Medicine. Palo Alto, CA. Laboratory Director: Mark Kay M.D., Ph.D.

2/04-12/05 Research Coordinator, Division of Gastroenterology, University of Washington School of Medicine. Seattle, WA. Employer: Kris Kowdley, MD

12/05-7/07 Research Scientist, Division of Gastroenterology, University of Washington School of Medicine. Seattle, WA. Employer: Kris Kowdley, MD

7/07-1/13 Staff Scientist, Kowdley Lab Manager, Benaroya Research Institute, Seattle, WA

1/13-5/15 Research Assistant Member, Benaroya Research Institute, Seattle, WA

Career Related Coursework

1

James E. Nelson, PhD

1989 “A Short Course in Molecular Biology Software”, Intelligenetics Inc., Detroit, MI

1992 NIDDK Symposium, “Impact of Molecular Genetics on the Treatment of Genetic Diseases”, Bethesda, MD

1994 “Introduction to SUNOS”, SUN microsystems Inc., Southfield, MI

1995-present “Animal Use; Laws and Regulations Training”, University of Washington

1995, 2006 “Animal Use; Specific Pathogen Free Training”, University of Washington

1995, 2006 “Mouse Hands-on Training Course”, University of Washington

2003 “Human Subjects Research Training”, University of Washington, Seattle, WA

2004 “Introduction to Microsoft Access”, UW Computer Training, Seattle, WA

2004 “Intermediate Microsoft Access”, UW Computer Training, Seattle, WA

2004 “NIH Regional Seminars in Program Funding and Grants Administration”, Seattle

2005 “Design of a Clinical Research Trial Summer Course”, UW GCRC, Seattle, WA

2005-2007 “Bloodborne Pathogens for Researchers Training”, University of Washington

2005-present “Human Research Course”, CITI Collaborative Institutional Training Initiative

2006 “Integrating Quality in Clinical Trials: Update on Clinical Trial and IRB Management of Studies”, FDA Center for Devices and Radiological Health (CDRH) and the Organization for Regulatory and Clinical Associates (ORCA), Kirkland, WA

2007-present “GCP Training Course”, Clinical Research Training for Investigational Site Personnel (CRISP) Sponsored by ClinfoSource and the UW School of Medicine

2008-present “Working with the IACUC”, CITI Collaborative Institutional Training Initiative

2008-present “Specific Pathogen Free Training”, Benaroya Research Institute

2008-present “Occupational Health and Safety Training”, Benaroya Research Institute

2008-present “Radiation Safety Training”, Benaroya Research Institute

2009 NIDDK Symposium, “Iron Overload Disorders”, Bethesda, MD

2010 Northwest Center for Public Health Practice “Online Course in Epidemiology”

2010 AASLD Basic Research Workshop – “Progenitors, Precursors, and Non-Parenchymal Cells in Liver Fibrosis”, Boston, MA

2011 Manager Online Training, “Workplace Answers”, Benaroya Research Institute

2011 “Working with Rats”, University of Washington, Seattle, WA

2011 “Rat Hands-on Training Course”, University of Washington

2011 AASLD Basic Research Workshop – “MicroRNAs in Liver Diseases”, San Francisco, CA

2012 EASL Monothematic Conference, “IMLI – Immune-Mediated Liver Injury,” Birmingham, UK

2012 AASLD Basic Research Single Topic Conference – “Mitochondria and Hepatotoxicity” Atlanta, GA

2


2012 “Conflict of Interest; mini-course”, CITI Collaborative Institutional Training Initiative

2013 “Writing/Designing NIH Proposals Workshop” Sponsored by the Grant Training Center, University of Washington, Seattle, WA

2014 AASLD Basic Research Single Topic Conference – “Non coding RNAs in Liver Function and Dysfunction”, Miami, FL

2014 “Learning R / Bioconductor for Sequence Analysis”, Fred Hutchinson Cancer Research Center, Seattle, WA

RESEARCH SUPPORTCompleted1994-1997 Cystic Fibrosis Foundation Postdoctoral Fellowship (Nelson)

1997-1998 NIDDK Training Grant- Postdoctoral Fellowship, Division of Gastroenterology, University of Washington School of Medicine (Lee)

2002-2014 NIDDK [U01DK061728-12], Research Network in Nonalcoholic Steatohepatitis (Kowdley). Role: Staff Scientist

2005-2009 NIDDK [U01DK61728-03S1], Iron Depletion Therapy for Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Kowdley). Role: Staff Scientist

2005-2009 NIDDK [U01DK61728-03S2], A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Dietary Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease (Kowdley). Role: Staff Scientist

2007-2011 NIDDK [R21DK072360], Room Temperature Susceptometry for Hepatic Iron Measurement (Kowdley). Role: Other Significant Contributor

2009-2010 Calistoga Pharmaceuticals, Seattle, WA. Effect of Phosphoinositide 3-Kinase P110delta Inhibition in a Murine Model of NASH (Kowdley). Role: Co-Investigator

2010-2011 NIDDK [R56DK087696], The Role of Iron in the Pathogenesis of NAFLD (Kowdley). Role: Co-Investigator

2011-2015 NIDDK [R01DK087696-03], The Role of Iron in the Pathogenesis of NAFLD (Kowdley). Role: Co-Investigator

2012-2013 The American College of Gastroenterology [ACG-CR-072-2012], The Relationship Between Serum Vitamin D Levels and NASH Severity (Kowdley). Role: Co-Investigator

2012-2014 NHLBI [R21HL112678-02], Serum Biomarkers Associated with Phenotypic Expression of Hemochromatosis (Kowdley). Role: Co-Investigator

2013-2014 Gilead Sciences, Inc. Expression of PI3Kdelta and Activation Status of this Pathway in Liver Tissue Samples From NASH Patients. Role: PI

2013-2014 VMMC Digestive Disease Institute, Defining the Hepatic Immune Response to Vitamin D Deficiency in Humans and Rats with Nonalcoholic Steatohepatitis. Role: PI

3


2013-2014 Benaroya Research Institute, Wilske Center for Translational Research Pioneer Award, Serum MicroRNA Profiling in NAFLD. Role: PI

2013-2015 NIDDK [R21DK099718-01], Novel Prognostic MicroRNA Biomarkers for Primary Sclerosing Cholangitis (Kowdley). Role: Co-Investigator

2014-2019 NIDDK [U01DK061728-14], Research Network in Non-alcoholic Steatohepatitis (Kowdley). Role: Co-Investigator

AWARDS1981 Eagle Scout

1988-1991 Graduate Research Assistantship I, W.S.U. School of Medicine

1991-1994 Graduate Research Assistantship II, W.S.U. School of Medicine

1992 NIH Travel Grant to attend the NIDDK Symposium on the Impact of Molecular Genetics on the Treatment of Genetic Diseases

1993 The Institute for Genome Research T.I.G.R. Travel Grant to attend the Genome Sequencing and Analysis Conference V

1993 Wayne State University Travel Award to attend the Genome Sequencing and Analysis Conference V

2007 The International BioIron Society, Travel Award to attend BioIron 2007

2011 Presidential Poster of Distinction, Digestive Disease Week 2011: Relationship of C282Y HFE Mutations, Hepatic Iron Deposition and Histologic Features in Patients with Nonalcoholic Fatty Liver Disease.

2011 Presidential Poster of Distinction, AASLD 2011:C282Y HFE Mutations Contribute to Decreased Circulating Hepcidin Levels and Increased Hepatocellular Iron Deposition in Patients with Nonalcoholic Fatty Liver Disease.

2012 Presidential Poster of Distinction, AASLD 2012: The Il1β +3953 C>T polymorphism minor allele is associated with a higher NAFLD activity score, presence of nonalcoholic steatohepatitis and is an independent risk factor for advanced fibrosis in subjects with nonalcoholic fatty liver disease.

PROTOCOLS AND STUDIES DESIGNED1995 Second Generation Adenoviral Vectors for Liver-Directed Gene Therapy. Funding: Cystic

Fibrosis Foundation

1997 Minimal Adenovirus Gene Therapy Vectors. Funding: NIDDK Training Grant Postdoctoral Fellowship

2005 Iron Depletion Therapy for Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. NASH CRN Pilot and Feasibility Study PF6. IRB#: 07049-UW. Funding: NIDDK U01 K061728-03S1; ClinicalTrials.gov ID NCT00230113

2005 A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Dietary Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease. NASH CRN Pilot and Feasibility Study PF7. IRB#: 07050-UW.

4


Funding: NIDDK U01 DK061728-03S2; ClinicalTrials.gov ID NCT00230087

2006 Room Temperature Susceptometry for Hepatic Iron Measurement. IRB#: 07031-BRI. Funding: NIDDK R21 DK072360

2006 Effect of Liver Transplantation on Duodenal Iron Transporter Gene Expression in a Hfe Knockout Mouse Model. ACUC Protocol #: 4101-UW. Funding: Private

2006 Prevalence and Pattern of Hepatic Iron Deposition and Relationship to Type 2 Diabetes and Fibrosis among Patients with NAFLD: Preliminary findings from the NASH CRN. NASH CRN MS#2006-3

2007 The Relationship of BMI, the Metabolic Syndrome and NAFLD. NASH CRN MS#2007-4

2008 Generation of a Dietary Mouse Model for NASH. ACUC Protocol #: 07KO01- BRI. Funding: Private

2008 Effects of Dietary and Parenteral Iron Loading in a Mouse Model of NASH. ACUC Protocol #: 07KO02-BRI. Funding: Private

2008 The Relationship of Hyperferritinemia and NAFLD. NASH CRN MS#2008-6

2008 Effect of Pioglitazone in an Iron Loaded Murine Model of NAFLD. Submitted to Takeda Pharmaceuticals North America, Inc.; not funded

2009 T he Relationship of Hepatic Iron Phenotype, Serum Ferritin Levels and NASH Pathogenesis . NASH CRN Ancillary Study AS40; IRB#:09002-BRI. Funding: NIDDK K24 DK002957; R56 DK087696; 1R01 DK087696

2009 Translational Research in NAFLD. IRB#: 09002-BRI. Funding: NIDDK K24 DK002957; R56 DK087696; 1R01 DK087696

2009 The Effect of PI3-Kinase p110Δ Inhibition in a Murine Model of NASH. ACUC Protocol #: 07KO03-BRI. Funding: Calistoga Pharmaceuticals, Inc

2009 The Relationship of Serum Ferritin and hsCRP in Patients with Nonalcoholic Fatty Liver Disease. IRB#: 09002-BRI. Funding: NIDDK K24 DK002957-08S1

2010 The Relationship between Serum Cytokines and miRNA Levels and Progression of PSC, Presence of Ulcerative Cholitis and Cholangiocarcinoma and Therapeutic Effect of UDCA. IRB#: 07032-BRI. Funding: NIDDK R01 DK056924-08S1

2010 Prevalence and features of iron deficiency and anemia among subjects in the NASH CRN. NASH CRN MS#2010-10

2010 The Relationship of Hemochromatosis Gene HFE Mutations and NAFLD. NASH CRN MS#2010-11

2011 Serum Biomarkers Associated With Phenotypic Expression of Hemochromatosis. IRB#: 11075-BRI. Funding: NHLBI R21HL116878-01

2011 Role of Vitamin D Deficiency and the Intestinal Microbiome in a Rat Model of NAFLD. ACUC Protocol #: 07KO02-BRI. Not funded

2012 The Relationship between Serum Vitamin D Levels, NASH Diagnosis, and NAFLD Activity Score. NASH CRN Ancillary Study AS64. IRB#: 09002-BRI. Funding: ACG-CR-072-2012

5


2012 Identification of Novel Micro-RNAs in a Rat Model of Cholangiocarcinoma*. ACUC Protocol #: 12KO01-BRI. Funding: BRI. *Co-designed with Bart Rose, MD and Yu Li, PhD

2013 Effect of Iron Deposition in NAFLD: A Longitudinal Study. NASH CRN MS#2013-2

2013 Defining the Hepatic Immune Response to Vitamin D Deficiency in Humans and Rats with Nonalcoholic Steatohepatitis. IRB#: 09002-BRI. Funding: VMMC Digestive Disease Institute

2013 An Integrative Transcriptomic Approach to Define Novel Diagnostic and Prognostic Serum Extracellular RNA (exRNA) Biomarkers for Nonalcoholic Steatohepatitis. NASH CRN Ancillary Study AS76. IRB#: 09002-BRI. Funding: Wilske Center for Translational Research Pioneer Award

2013 Development of a miRNA Based In Vitro Diagnostic Device for the Prognosis of NAFLD. Submitted to the BRI Commercialization Gap Funding Program; not funded

2013 Novel Prognostic MicroRNA Biomarkers for Primary Sclerosing Cholangitis. IRB#: 07032-BRI. Funding: NIDDK R21DK099718

2014 The IL1B rs1143634 Rare Allele Increases the Risk of Nonalcoholic Steatohepatitis and Advanced Fibrosis. NASH CRN MS#2014-3

2014 Serum Vitamin D Deficiency is Associated with Nonalcoholic Steatohepatitis in Adults. NASH CRN MS#2014-7

SERVICE1991-1992 Curriculum Committee, Department of Molecular Biology and Genetics, Wayne

State University School of Medicine

1992-1993 Guest Speaker Committee Department of Molecular Biology and Genetics, Wayne State University School of Medicine

2006-2007 Member, “Working Group For Lean Alignment”, University of Washington Clinical Research Center

2006-2011 NASH Clinical Research Network Steering Committee Representative

2012-2014 Member, Benaroya Research Institute Safety Committee

2012-2015 Member, AASLD Steatosis and Steatohepatitis Special Interest Group

2012-2015 Member, AASLD Liver Fibrosis Special Interest Group

Reviewer: BioTechniques, Journal of Virology, Gene Therapy, Human Gene Therapy, Gastroenterology, Hepatology, Molecular Medicine, Journal of Cellular Biochemistry, Alimentary Pharmacology & Therapeutics, Journal of Clinical Gastroenterology, Tissue and Cell, Journal of Hepatology,

PROFESSIONAL SOCIETY MEMBERSHIPS1995-1999 American Association for the Advancement of Science

1997-1999 American Society for Human Gene Therapy (invited membership)

6


2005-2015 International BioIron Society

2009-2015 American Association for the Study of Liver Disease

2010-present Northwest Institute of Genetic Medicine

2010-present Institute for Translational Health Sciences

SELECTED PRESENTATIONS1996 “Adenoviral Vectors for Liver-Directed Gene Therapy”, Cystic Fibrosis Foundation,

Seattle WA.

1997 “Third Generation Adenoviral Vectors”, Cystic Fibrosis Foundation, Seattle WA.

1998 “Minimal Adenovirus Gene Therapy Vectors”, Division of Gastroenterology, Dept. of Medicine, University of Washington, Seattle, WA.

1998 “The Role of Host Immune Responses in the Persistence of minAD Vectors”, Seattle Gene Therapy Club, Seattle, WA.

1998 “Principles of Gene Therapy” Fred Hutchinson Cancer Research Center, Outreach Program, Seattle, WA.

2007 “Iron Depletion Therapy for Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease”. NASH Clinical Research Network Steering Committee Meeting, Baltimore, MD

2008 “A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Dietary Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease”. NASH Clinical Research Network Steering Committee Meeting, Baltimore, MD

2009 “Iron in Hepatic Reticulendothelial Cells is Associated with Histologic Severity in Nonalcoholic Fatty Liver Disease” NASH Clinical Research Network Steering Committee Meeting, Baltimore, MD

2011 “Relationship of C282Y HFE Mutations, Hepatic Iron Deposition and Histologic Features in Patients with Nonalcoholic Fatty Liver Disease”. International Congress of the BioIron Society, Vancouver, Canada

2011 “Iron, Immunity and Liver Disease” Benaroya Research Institute Work-In-Progress Seminar, Seattle WA

2013 “Reticuloendothelial Cell System Iron Staining is a Predictor of Progression to Borderline or Definite Steatohepatitis in Patients without Fibrosis”. NASH Clinical Research Network Steering Committee Meeting, Baltimore, MD

2014 “Development of Serum Based miRNA Biomarkers for the Diagnosis and Prognosis of NAFLD” Benaroya Research Institute Work-In-Progress Seminar, Seattle WA

PUBLICATIONSOriginal Articles1. Nelson JE, Krawetz SA. Purification of cloned and genomic DNA by guanidine thiocyanate

/isobutyl alcohol fractionation. Anal Biochem. 1992 Nov 15;207(1):197-201.

7


2. Nelson JE, Krawetz SA. Linkage of human spermatid-specific basic nuclear protein genes: definition and evolution of the P1P2TP2 locus. J Biol Chem. 1993 Feb 5;268(4):2932-6.

3. Nelson JE, Krawetz SA. Easy-read DNA sequencing gels. Biotechniques 1994 Sep;17(3):416-418.

4. De Jonckheere J, Nelson JE, Ginsburg KA, Krawetz SA. GA repeat polymorphism at the PRM2 male fertility locus of chromosome 16. Hum Mol Genet. 1994 Oct;3(10):1915.

5. Nelson JE, Krawetz SA. Characterization of a human locus in transition. J Biol Chem. 1994; Dec 9;269(49):31067-73.

6. Singh GB, Nelson JE, McALinden TP, Krawetz SA. ISWAC:Proposed system for the integrated assembly of chromosomes. DNA Seq. 1994;5(2):67-76.

7. Nelson JE, Krawetz SA. Mapping the clonally recombinogenic PRM1PRM2TNP2 region of human 16p13.2. DNA Seq. 1995;5(3):163-8.

8. Wykes SM, Nelson JE, Visscher DW, Djakiew D, Krawetz SA. Coordinate expression of the PRM1, PRM2 and TNP2 multigene locus in human testis. DNA Cell Biol. 1995 Feb;14(2):155-61.

9. Choudhary SK, Wykes, SM, Kramer JA, Anwar M, Koppitch F, Nelson JE, Krawetz SA. A haploid expressed gene cluster exists as a single chromatin domain in human sperm. J Biol Chem. 1995 Apr 14;270(15):8755-62.

10. Nelson JE, Krawetz SA. Computer assisted promoter analysis of human sperm specific nucleoprotein cluster. DNA Seq. 1995;5(6):329-37

11. Nelson JE, Kay MA. Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J Virol. 1997 Nov;71(11):8902-7. PMCID: PMC192362,

12. Nelson JE, Bhattacharya R, Raaka S, Lindor KD, Heathcote EJ, Chalasani N, Shaffer E, Miskovsky E, Rulyak SJ, Kowdley KV. The C282Y HFE mutation is associated with advanced fibrosis in non-alcoholic steatohepatitis. Hepatology 2007 Sep;46(3):723-9.

13. Bares JM, Berger J, Nelson JE, Messner DJ, Schildt S, Tung BY, Standish LJ, Kowdley KV. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol. 2008 Sep;42(8):937-44.

14. Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J; Nonalcoholic Steatohepatitis Clinical Research Network, [Nelson JE]. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008 Dec;135(6):1961-1971. PMCID: PMC2628583.

15. David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB; NASH CRN Research Group, [Nelson JE]. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009 Jun;49(6):1904-12. PMCID: PMC2692572.

16. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; NASH Clinical Research Network, [Nelson JE]. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. PMCID: PMC3079239.

17. Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis

8


Clinical Research Network Research Group [Nelson JE]. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials. 2010 Jan;31(1):62-70. PMCID: PMC2936451.

18. Nelson JE, Mugford VR, Kilcourse E, Wang RS, Kowdley KV. Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects. Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1):G57-62. PMCID: PMC2806103.

19. Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) [Nelson JE]. Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010 Feb 1;31(3):396-406. PMCID: PMC2807909.

20. Sanyal A, Chalasani N, Kleiner D, Brunt E, Robuck P, Unalp-Arida A, Tonascia J; NASH Clinical Research Network [Nelson JE]. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85. PMCID: PMC2928471.

21. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network [Nelson JE]. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010 Jun;51(6):1961-71. PMCID: PMC2922495.

22. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network [Nelson JE]. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010 Sep;52(3):913-24. PMCID: PMC3070295.

23. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Ünalp A, Kowdley KV and the NASH CRN Research Group. Relationship between pattern of hepatic iron deposition and histologic severity in nonalcoholic fatty liver disease. Hepatology. 2011 Feb;53(2):448-57. PMCID: PMC3058264.

24. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O'Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS; NASH CRN; GIANT Consortium; MAGIC Investigators, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB; GOLD Consortium [Nelson JE]. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011 Mar;7(3):e1001324. PMCID: PMC3053321.

25. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN) [Nelson JE]. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011 Mar;53(3):810-20. PMCID: PMC3079483.

26. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group [Nelson JE]. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011 Mar;106(3):460-8. PMCID: PMC3070294.

27. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network

9

http://www.ncbi.nlm.nih.gov/pubmed/20648476








[Nelson JE]. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011 Apr 27;305(16):1659-68. PMCID: PMC3110082.

28. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012 Jan;55(1):77-85. PMCID: PMC3245347.

29. Maliken BD, Avrin WF, Nelson JE, Mooney J, Kumar S, Kowdley KV. Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin. Ann Heptol. 2012 Jan-Feb; 11(1): 77-84. PMCID: PMC3499026.

30. Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, Schwimmer JB,Tonascia J, Unalp A, Lavine JE; NASH CRN Research Group [Nelson JE]. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):90-6. PMCID: PMC3208079.

31. Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N; Nonalcoholic Steatohepatitis Clinical Research Network Research Group [Nelson JE]. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012 Mar;55(3):769-80. PMCID: PMC3278533.

32. Roth CL, Elfers C, Lattemann D, Hoofnagle A, Morton GJ, Yeh MM, Nelson JE, Kowdley KV. Vitamin D deficiency in obese rats exacerbates NAFLD and increases hepatic resistin and toll-like receptor activation. Hepatology 2012 Apr;55(4):1103-11.

33. Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A, Diehl AM; NASH CRN. [Nelson JE]. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology. 2012 Jun;55(6):1711-21. PMCID: PMC3499103.

34. Guy CD, Suzuki A, Burchette JL, Brunt EM, Abdelmalek MF, Cardona D, McCall SJ, Ünalp A, Belt P, Ferrell LD, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network. [Nelson JE]. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol. 2012 Jun;43(6):790-800. PMCID: PMC3288773.

35. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network [Nelson JE]. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012 Sep;56(3):943-51. PMCID: PMC3407289.

36. Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network [Nelson JE]. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012 Oct;56(4):1311-8. PMCID: PMC3432683.

37. Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE genotypes. Hepatology 2012 Nov;56(5):1730-1740. PMCID: PMC3462887.

10


38. Maliken BD, Nelson JE, Yeh MM, Klintworth H, Beauchamp M, Kowdley KV. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology. 2013 May;57(5):1806-13. PMCID: PMC3637923.

39. Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander Tetri BA, Sanyal AJ, Tonascia J; the Non-alcoholic Steatohepatitis Clinical Research Network [Nelson JE]. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013 Jul;38(2):134-43. PMCID: PMC3775262.

40. Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, Behling C, Loomba R; NASH CRN [Nelson JE]. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013 Nov;58(5):1644-54.

41. Bambha K, Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM; for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) [Nelson JE]. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014 Sep;34(8):1250-8.PMID: 24267865.

42. Handa P, Maliken BD, Nelson JE, Morgan-Stevenson V, Dhillon BK, Klintworth HM, Beauchamp M, Yeh MM, Elfers CT, Roth CL, Kowdley KV. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology. 2014 Jul;60(1):133-45. PMID: 24464605

43. Utzschneider KM, Largajolli A, Bertoldo A, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Kahn SE. Serum ferritin is associated with nonalcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women. J Diabetes Complications. 2014 Mar-Apr;28(2):177-84. PMCID: PMC3943487.

44. Kratz M, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Callahan HS, Song X, Di C, Utzschneider KM. Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans. Am J Clin Nutr. 2014; 99:1385-96. PMCID: PMC4021783.

45. Siddique A*, Nelson JE*, Aouizerat B, Yeh MM, Kowdley KV; for the NASH Clinical Research Network. Iron deficiency in patients with nonalcoholic fatty liver disease is associated with obesity, female sex, and low serum hepcidin. Clin Gastroenterol Hepatol. 2014 Jul;12(7):1170-8. PMCID: PMC4028425. *These authors contributed equally.

46. Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N; NASH CRN [Nelson JE]. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Aliment Pharmacol Ther. 2015 Feb;41(3):301-9.

47. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network CRN [Nelson JE]. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956-65.

48. Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network [Nelson JE]. Improvement in liver histology is associated with reduction in dyslipidemia in

11


children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7.

49. Handa P, Morgan-Stevenson V, Maliken BD, Nelson JE, Washington S, Westerman M, Yeh MM, Kowdley KV. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. Am J Physiol Gastrointest Liver Physiol. 2016 Jan 15;310(2):G117-27.

50. Nelson JE, Roth C, Wilson L, Yates K, Whalen E, Aouizerat B, Morgan-Stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV; for the NASH Clinical Research Network. Vitamin D deficiency is associated with increased risk of nonalcoholic steatohepatitis in adults with nonalcoholic fatty liver disease: possible role for MAPK and NF-κB? Am J Gastroenterol. 2016 Mar 22. [Epub ahead of print]

51. Nelson JE, Aouizerat B, Wilson L, Yeh MM, Kowdley KV; for the NASH Clinical Research Network. Association of IL1B and IL6 Polymorphisms with Steatohepatitis and Parenchymal Damage in Caucasians with Nonalcoholic Fatty Liver Disease. In revision for Liver International.

52. Kanwar P, Nelson JE, Yates K, Unalp-Arida A, Kowdley KV; for the NASH Clinical Research Network Relationship of obesity, metabolic syndrome and insulin resistance to NASH. In Revision for Ann Heptol.

53. Handa P, Gupta R, Dhillon BK, Nelson JE, Maliken BD, Yeh MM, Kowdley KV. Iron, inflammation and oxidative stress-mediated regulation of hepcidin gene expression in patients with nonalcoholic steatohepatitis. Submitted to Clinical Gastroenterology and Hepatology.

Manuscripts in Preparation1. Nelson JE, Whalen E, Morgan-Stevenson V, Sendler E, Gersuk V, Yeh MM, Krawetz S,

Kowdley KV. Integrated transcriptomics define novel molecular networks and prognostic serum extracellular RNA biomarkers for nonalcoholic steatohepatitis. In preparation for submission to Science Translational Medicine.

2. Rose JB, Correa-Gallego C, Li Y, Nelson JE, Alseidi A, Helton S, Allen PJ, D’Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Kowdley KV, Jarnagin WR, Rocha FG. The Role of Biliary Carcinoembryonic Antigen-related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. In preparation for submission to Clinical Cancer Research.

Invited Reviews and Letters1. Nelson JE, Kowdley KV. Iron and hepatitis C. Curr Hepatol Rep. 2005 3(4):140-147.

2. Nelson JE, Kowdley KV. Non-HFE Hemochromatosis: genetics, pathogenesis and clinical management. Curr Gastroenterol Rep. 2005 7:71–80.

3. Nelson JE, Kowdley KV. Letter to the editor: Reply Valenti et.al., Hepatology 2008 May;47(5):1795-6.

4. Nelson JE, Kowdley KV. IKKε: A potential therapuetic target for obesity (and nonalcoholic fatty liver disease)? Hepatology. 2010 Jan;51(1):336-8.

5. Nelson JE, Kowdley KV. Letter to the editor: Author Reply Manco et.al.,The wide spectrum of hepatic iron overload. Hepatology. 2011 Mar;53(3):1057-8; author reply 1058-9

12


6. Maliken BD, Nelson JE, Kowdley KV. The hepcidin circuits act: balancing iron and inflammation. Hepatology. 2011 May; 53(5): 1764-1766.

7. Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2012 Feb;14(1):8-16.

8. Nelson JE, Kowdley KV. Letter to the editor: Author Reply Paul et.al., Interaction of serum ferritin and body mass index in patients with chronic hepatitis B: Improved prediction of cirrhosis. Hepatology. 2013 May;57(5):2095.

9. Shah N, Nelson JE, Kowdley KV. MicroRNAs in Liver Disease: Bench to Bedside. J Clin Exp Hepatol. 2013 Sep;3(3):231-42.

Book Chapters1. Nelson, JE, Khidir, M. and Krawetz, SA. Purification of DNA with guanidine thiocyanate and

isobutyl alcohol fractionation. CELL BIOLOGY: A LABORATORY HANDBOOK (ed. J.E. Celis) Academic Press Inc. 1994 (1);674-679.

2. Nelson JE, Trinder D, Kowdley KV. Hemochromatosis. Molecular Pathology of Liver Diseases, Molecular Pathology Library 5 (ed., S.P.S. Monga) Springer Science LLC. 2010; 665-676.

Abstracts1. Nelson, JE, Twomey, TA and Krawetz, SA. (1990) Resources for the human genome project.

Cold Spring Harbor Genome Mapping and Sequencing:128.

2. Nelson JE, Krawetz SA. (1992) Analysis and evolution of the human protamine locus. Fisher Scientific Winternational Symposium "Gene Expression during Gametogenesis" # 2.

3. Nelson, JE and Krawetz, SA. (1992) Characterization of the human protamine locus. Great Lakes Mammalian Development Meeting.

4. Nelson JE, Krawetz SA. (1993) High resolution analysis of the human P1P2 TP2 locus. Genome Sequencing and Analysis Conference V:41.

5. Nelson JE, Krawetz SA. (1994) Analysis of the highly repetitive human P1P2 TP2 locus. Great Lakes Mammalian Development Meeting.

6. Wykes SM, Nelson JE, Visscher DW, Djakiew D, Krawetz SA. (1994) Expression of the human PRM1, PRM2 and TNP2 testis specific genes. Great Lakes Mammalian Development Meeting.

7. Choudhary SK, Nelson JE, Krawetz SA. (1994) Locus activation of the human protamine domain. Great Lakes Mammalian Development Meeting.

8. Nelson JE, Kay MA (1996) Minimal adenoviral vectors for gene therapy. Cold Spring Harbor Gene Therapy Meeting:227.

9. Nelson JE, Bhattacharya R, Raaka S, Lindor KD, Heathcote EJ, Chalasani N, Shaffer E, Miskovsky E, Rulyak SJ, Kowdley KV (2005) Association of HFE mutations and advanced fibrosis in patients with NASH. International Congress of the BioIron Society.

10. Nelson JE, Bhattacharya R, Raaka S, Lindor KD, Heathcote EJ, Chalasani N, Shaffer E, Miskovsky E, Rulyak SJ, Kowdley KV (2005) Association of HFE mutations and advanced fibrosis in patients with NASH. Presented at AASLD 2005. Hepatology, 42:1066.

11. Nelson JE, Raaka S, Li W, Kowdley KV (2007) Murine liver transplantation model in Hfe

13


knockout mice: preliminary results on expression of Hamp and duodenal iron transport genes. International Congress of the BioIron Society.

12. Nelson JE, Yates K, Ünalp A, Kowdley KV for the NASH CRN Research Group: (2007) Relationship of BMI, metabolic syndrome, and NASH in adults. Presented at AASLD. Hepatology, 2007;46: 742A, 2007, Supplement 1.

13. Nelson JE, Belt P, Wilson LA, Yeh MM, Kowdley KV, for the NASH CRN Research Group. (2008) Serum ferritin is associated with the presence of NASH, increased ALT, AST and histologic severity among patients with NAFLD. Presented at AASLD. Hepatology, 2007;48:1126A, 2008, Supplement 1.

14. Nelson JE, Maliken B, Saunders C, Stevenson J, Richards TL, Kowdley KV. (2009) A randomized, masked, controlled study of omega-3 polyunsaturated fatty acid vs monounsaturated fatty acid diet supplementation for the treatment of nonalcoholic fatty liver disease. Presented at DDW. Gastroenterology, 2009;136: A847-A848, 2009, Supplement 1.

15. Nelson JE, Utzschneider K, Maliken B, Alexander J, Kowdley KV. (2009) Iron depletion therapy for patients with metabolic syndrome and non-alcoholic fatty liver disease: preliminary findings. International Congress of the BioIron Society.

16. Nelson JE, Raaka S, Mugford VR, Kilcourse E, Kowdley KV. (2009) Differences in gene expression of duodenal iron transporters among hemochromatosis subjects with and without iron overload. International Congress of the BioIron Society.

17. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner D, Ünalp-Arida A, Kowdley, KV for the NASH CRN. (2009) Hepatic iron deposition in reticuloendothelial cells but not hepatocytes is associated with more severe NASH: results from the NASH Clinical Research Network. International Congress of the BioIron Society.

18. Maliken BD, Nelson JE, Dhillon BK, Yeh MM, Beauchamp M, Roth C, Kowdley KV. (2010) Combining genetic and dietary factors in creation of a novel murine model of nonalcoholic steatohepatitis (NASH). Presented at DDW. Gastroenterology, May 2010;138(5):S-801, Supplement 1.

19. Dhillon BK, Nelson JE, Maliken BD, Yeh MM, Beauchamp M, Roth C, Kowdley KV. (2010) Hepatic hepcidin expression in an obese diabetic model of nonalcoholic steatohepatitis (NASH) Presented at DDW. Gastroenterology, May 2010;138(5):S-801, Supplement 1.

20. Nelson JE, Mooney J, Avrin W, Kowdley KV. (2010) Room temperature susceptometry for hepatic iron measurement. Presented at AASLD. Hepatology, 2010;52:500A, 2010, Supplement 1.

21. Nelson JE, Yeh M, Kowdley KV. (2011) Relationship of C282Y HFE Mutations, Hepatic Iron Deposition and Histologic Features in Patients with Nonalcoholic Fatty Liver Disease. Presented at Digestive Disease Week. Gastroenterology, 2011;140:S-938-S-939. Suppl 1. Presidential Poster of Distinction & Invited Video Presentation;SU1852.

22. Nelson JE, Belt P, Wilson L, Yeh M, Tetri BA, Chalasani NP, Sanyal AJ, Kowdley, KV. (2011) Elevated serum ferritin values above the upper limit of normal are associated with laboratory and histologic evidence of increased NASH severity, but not the presence of diabetes or metabolic syndrome among patients in the NASH CRN. Presented at Digestive Disease Week. Gastroenterology, 2011;140:S-727. Suppl 1.

23. Siddique A, Nelson JE, Yeh M, Kowdley KV. (2011) The relationship between obesity, metabolic syndrome and iron deficiency in NAFLD. Presented at Digestive Disease Week.

14


Gastroenterology, 2011;140:S-703. Suppl 1.

24. Nelson JE, Mooney J, Avrin W, Kowdley KV (2011) Room temperature susceptometry for hepatic iron measurement. Presented at International Congress of the BioIron Society.

25. Nelson JE, Belt P, Wilson L, Yeh M, Tetri BA, Chalasani NP, Sanyal AJ, Kowdley, KV. (2011). Elevated serum ferritin values above the upper limit of normal are associated with laboratory and histologic evidence of increased NASH severity, but not the presence of diabetes or metabolic syndrome among patients in the NASH CRN. Presented at International Congress of the BioIron Society.

26. Siddique A, Nelson JE, Yeh M, Kowdley KV. (2011). The relationship between obesity, metabolic syndrome and iron deficiency in NAFLD. Presented at International Congress of the BioIron Society.

27. Maliken BD, Nelson JE, Dhillon B, Yeh MM, Kowdley KV. (2011) Hyperferritinemia in nonalcoholic fatty liver disease: the effects of obesity-related chronic inflammation and increased body iron stores. Presented at International Congress of the BioIron Society.

28. Roth CL, Elfers C, Lattemann D, Hoofnagle A, Morton GJ, Yeh MM, Nelson JE, Kowdley KV. (2011) Vitamin D deficiency contributes to insulin resistance and NAFLD in obese rats. The Endocrine Society’s 93rd Annual Meeting, Boston, poster P3-392.

29. Nelson JE, Yeh MM, Dhillon BK, Kowdley KV. (2011) C282Y HFE mutations contribute to decreased circulating hepcidin levels and increased hepatocellular iron deposition in patients with nonalcoholic fatty liver disease. Presented at AASLD. Presidential Poster of Distinction. Hepatology, 2011;54(4):1113A. Supplement.

30. Dhillon BK, Nelson JE, Maliken BD, Yeh MM, Kowdley KV. (2011). Liver hepcidin gene expression in patients with NAFLD is induced by both hepatic necroinflammation and iron stores. Presented at AASLD. Hepatology, 2011;54(4):1142A. Supplement.

31. Maliken BD, Klintworth H, Yeh MM, Nelson JE, Kowdley KV. (2011). Hepatic iron deposition is associated with increased apoptosis and oxidative stress among patients with NAFLD. Presented at AASLD. Hepatology, 2011;54(4):1126A, 2011, Supplement.

32. Maliken BD, Nelson JE, Dhillon BK, Beauchamp, M, Yeh MM, Kowdley KV. (2011) Use of ferritin/CRP ratio to distinguish iron overload in NAFLD patients with hyperferritinemia: the effects of obesity-related chronic inflammation and increased body iron stores. Presented at AASLD. Hepatology, 2011;54(4):1145A, 2011, Supplement.

33. Nelson JE, Maliken BD, Klintworth H, Yeh MM, Kowdley KV. (2012). A high fat diet and parenteral iron causes increased inflammation and oxidative stress but less steatosis in an obese, diabetic mouse model of NAFLD. Presented at EASL Monothematic Conference on "Immune Mediated Liver Injury" Stratford-upon-Avon, UK, January 19-21, 2012.

34. Handa P, Maliken BD, Nelson JE, Yeh MM, Kowdley KV. (2012). Obesity causes adiponectin depletion and non-alcoholic steatohepatitis in Lepr db/db mice fed an unsaturated fat-rich diet. Presented at FASEB Liver Biology: Fundamental Mechanisms & Translational Applications, Snowmass, CO.

35. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdley KV. (2012). Vitamin D deficiency activates hepatic toll-like receptors and exacerbates NAFLD in obese rats. European Society for Pediatric Endocrinology. Hormone Research, 2012;78. Suppl.1.

15


36. Nelson JE, Yeh MM, Kowdley KV. (2012) The Il1β +3953 C>T polymorphism minor allele is associated with a higher NAFLD activity score, presence of nonalcoholic steatohepatitis and is an independent risk factor for advanced fibrosis in subjects with nonalcoholic fatty liver disease. Presidential Poster of Distinction. Hepatology, 2012;56(4):883A. Supplement.

37. Nelson JE, Maliken BD, Yeh MM, Klintworth H, Beauchamp M, Kowdley KV. (2012) Hepatic iron grade and pattern affects oxidative stress and apoptosis in NAFLD. Hepatology, 2012;56(4):890A. Supplement.

38. Handa P, Nelson JE, Maliken BD, Chua J, Yeh MM, Kowdley KV. (2012) Parenteral iron and a high fat diet cause increased inflammation, oxidative stress and apoptosis but decreased steatosis in an obese, diabetic mouse model of NAFLD. Hepatology, 2012;56(4):859A. Supplement.

39. Handa P, Nelson JE, Maliken BD, Yeh MM, Kowdley KV. (2012) A high unsaturated fat diet leads to NF-κB activation and increased hepatic macrophage and T cell accrual accompanies NF-κB activation in a diabetic, obese mouse model of NAFLD. Hepatology, 2012;56(4):865A. Supplement.

40. Rose JB, Correa-Gallego C, Nelson JE, Alseidi A, Helton S, Allen PJ, D'Angelica M, DeMatteo RP, Fong Y, Kingham PT, Kowdley K, Jarnagin WR, Rocha FG. (2013) Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma. ASCO GI Meeting, San Francisco, CA. J Clin Onc. Feb 2013;31(4):177.

41. Rose JB, Correa-Gallego C, Nelson JE, Alseidi A, Helton S, Allen PJ, D'Angelica M, DeMatteo RP, Fong Y, Kingham PT, Kowdley K, Jarnagin WR, Rocha FG. (2013) Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma. SSO Annual Meeting in National Harbor, MD. Ann Surg Onc. Mar 2013;20(1):S21.

42. Nelson JE, Maliken BD, Yeh MM, Klintworth H, Beauchamp M, Kowdley KV. (2013) Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Presented at International Congress of the BioIron Society, London UK, April 15-18, 2013.

43. Nelson JE, Yeh MM, Kowdley KV. (2013) Variants in the IL6 and IL1β genes modify the hepatic iron phenotype of patients with nonalcoholic fatty liver disease. Presented at International Congress of the BioIron Society, London UK, April 15-18, 2013.

44. Li Y, Shah N, Nelson JE, Lindor KD, Talwalkar J, Kowdley KV. (2013) Serum MicroRNA: Novel prognostic biomarkers in primary sclerosing cholangitis patients treated with high-dose ursodeoxycholic acid. Presented at DDW. Gastroenterology, 2013;144(5):S254, Supplement 1.

45. Nelson JE, Kleiner DE, Aouizerat BE, Kowdley KV. (2013) Variants in the Il6 and Il1β Genes either Alone or in Combination with C282Y HFE Mutations Modify the Hepatic Iron Phenotype of Patients with Nonalcoholic Fatty Liver Disease. Poster presented at the AASLD, 2013. Hepatology, 2013;58(4):490A, Supplement.

46. Kowdley KV, Kleiner DE, Wilson L, Belt PH, Nelson JE. (2013) Reticuloendothelial cell system iron staining is a predictor of progression to borderline or definite steatohepatitis in patients without fibrosis. Poster presented at the AASLD, 2013. Hepatology, 2013;58(4):516A, Supplement.

47. Handa P, Morgan-Stevenson V, Nelson JE, Maliken BD, Yeh MM, Kowdley KV. (2013) Dietary iron overload results in hepatic reticuloendothelial system cell iron accumulation,

16


oxidative stress, mitochondrial dysfunction, immune cell activation, and nonalcoholic steatohepatitis in obese, diabetic mice. Poster presented at the AASLD, 2013. Hepatology, 2013;58(4):555A, Supplement.

48. Handa P, Morgan-Stevenson V, Nelson JE, Maliken BD, Yeh MM, Elfers CT, Roth C, Kowdley KV. (2013) A high-fat diet results in nonalcoholic steatohepatitis, and adipose tissue hypoxia, macrophage infiltration and inflammatory M1 activation in obese diabetic mice. Poster presented at the AASLD, 2013. Hepatology, 2013;58(4):969A, Supplement.

49. Nelson JE, Sendler E, Krawetz SA, Kowdley KV. (2014) Deep sequencing identifies novel circulating and hepatic ncRNA profiles in nonalcoholic fatty liver disease patients. Presented at AASLD Basic Research Single Topic Conference – “Non coding RNAs in Liver Function and Dysfunction”, Miami, FL

50. Nelson JE, Sendler E, Krawetz SA, Kowdley KV. (2014) Serum microRNA biomarkers for prognosis of nonalcoholic fatty liver disease. Presented at AASLD Basic Research Single Topic Conference – “Non coding RNAs in Liver Function and Dysfunction”, Miami, FL

51. Handa P, Morgan-Stevenson V, Maliken BD, Li Y, Nelson JE, Yeh MM, Kowdley KV. High fat diet impairs hepatic microRNAs related to inflammation and macrophage infiltration contributing to nonalcoholic steatohepatitis in a mouse model with metabolic syndrome. Presented at AASLD Poster Session. Hepatology, October 2014;60(S1):499A.

52. Handa P, Morgan-Stevenson V, Maliken BD, Nelson JE, Yeh MM, Kowdley KV. Chronic dietary iron overload in genetically obese mice causes nonalcoholic steatosis, whereas acute iron excess leads to increased inflammation and reduced steatosis. Presented at AASLD Poster Session. Hepatology, October 2014;60(S1):520A.

53. Handa P, Morgan-Stevenson V, Maliken BD, Nelson JE, Yeh MM, Kowdley KV. Iron excess exacerbates proinflammatory and fibrogenic gene expression in genetically obese mice and in primary human hepatic stellate cells in response to TNF-α or TGF-β. Presented at AASLD Poster Session. Hepatology, October 2014;60(S1):583A.

54. Nelson JE, Wilson L, Roth C, Yeh MM, Kowdley KV. Serum vitamin D deficiency is associated with nonalcoholic steatohepatitis in adults. Presented at AASLD Poster Session. Hepatology, October 2014;60(S1):608A.

55. Karnik S, Charlton M, Nash M, Sulfab M, Barry V, Huntzicker EG, French D, Breckenridge D, Corkey B, Notte G, Nelson JE, Kowdley KV, Tumas D. Inhibition of MAP3K5, apoptosis signal-regulating kinase 1, with an oral small molecule inhibitor blocks hepatic fibrosis and steatosis in murine models of NASH and PSC. Presented at AASLD Poster Session. Hepatology, October 2014;60(S1):570A.

SEQUENCES DEPOSITED INTO INTERNATIONAL DATA BANKSGenBank and EMBL

1. Nelson JE, Krawetz SA. (1992) LO3378; Homo sapiens (chromosome 16), sperm-specific basic nuclear protein gene, TNP2

2. Nelson JE, Krawetz SA. (1994) HSU15422; Homo sapiens (chromosome 16), 40 kb of the human 16p13.13-16p13.2 region containing the protamine gene cluster

17


COMMUNITY SERVICE2008-2009 Coach, Eastlake Flag Football, Sammamish, WA

2009-present Member, PTSA, Margaret Mead Elementary School, Sammamish, WA

2009-2013 Den Leader, Cubscout Pack 551, Sammamish, WA

2011-2013 Cubmaster, Cubscout Pack 551, Sammamish, WA

2011-present Judge, “Science Fair”, Margaret Mead Elementary School, Sammamish, WA

2012-2015 Coach, Eastlake Little League Softball, Sammamish, WA

2015 Coach, Boys and Girls Basketball Program, Sammamish, WA

2015-present Coach, Bellevue Blast Select Softball, Sammamish, WA

18

James Nelson CV 33016

Documents

Transcript of James Nelson CV 33016